Document Detail

Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis.
MedLine Citation:
PMID:  17227619     Owner:  NLM     Status:  MEDLINE    
As the part of a study to develop buparvaquone (BPQ) formulations for the treatment of cutaneous leishmaniasis, the topical delivery of BPQ and one of its prodrugs from a range of formulations was evaluated. In previous studies, BPQ and its prodrugs were shown to be potent antileishmanials in-vitro, with ED50 values in the nanomolar range. 3-Phosphono-oxymethyl-buparvaquone (3-POM-BPQ) was the most potent antileishmanial and was chosen, together with the parent drug, for further investigation. The ability of the parent and prodrug formulations to cross human and murine skin was tested in-vitro using the Franz diffusion cells. Formulations intended for topical application containing either BPQ or 3-POM-BPQ were developed using excipients that were either acceptable for topical use (GRAS or FDA inactive ingredients) or currently going through the regulatory process. BPQ was shown to penetrate both human epidermal membranes and full thickness BALB/c skin from a range of formulations (gels, emulsions). Similarly, 3-POM-BPQ penetrated full-thickness BALB/c skin from several gel formulations. In-vitro binding studies showed that BPQ bound melanin in a dose-dependent manner and preferably bound to delipidized skin over untreated BALB/c skin (on a weight to weight basis). The results confirm that BPQ and its prodrug 3-POM-BPQ can penetrate the skin from several formulations, making them potentially interesting candidates for further investigation of topical formulations using in-vivo models of cutaneous leishmaniasis.
Tracy Garnier; Antti Mäntylä; Tomi Järvinen; M Jayne Lawrence; Marc B Brown; Simon L Croft
Related Documents :
1895329 - The macaque model for in vitro fertilization: superovulation techniques and ultrasound-...
17981269 - Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic ...
15955359 - The effect of gamete co-incubation time during in vitro fertilization with frozen-thawe...
16450409 - Mitochondrial organization in prepubertal goat oocytes during in vitro maturation and f...
16799739 - Correlation between number of retrieved oocytes and pregnancy rate after in vitro ferti...
9259959 - The human oocyte. genetic aspects.
8174719 - Serum progesterone predicts abnormal gestations in clomiphene citrate conception cycles...
14767249 - Interaction of step length and step rate during sprint running.
1172369 - Vitamin a transport in human fetal blood.
Publication Detail:
Type:  In Vitro; Journal Article    
Journal Detail:
Title:  The Journal of pharmacy and pharmacology     Volume:  59     ISSN:  0022-3573     ISO Abbreviation:  J. Pharm. Pharmacol.     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-01-17     Completed Date:  2007-04-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376363     Medline TA:  J Pharm Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  41-9     Citation Subset:  IM    
School of Pharmacy, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Cutaneous
Antiprotozoal Agents / chemistry,  metabolism*
Chemistry, Pharmaceutical
Ethanol / chemistry
Leishmaniasis, Cutaneous
Melanins / metabolism
Mice, Inbred BALB C
Myristates / chemistry
Naphthoquinones / chemistry,  metabolism*
Phosphoric Acid Esters / chemistry,  metabolism*
Polyethylene Glycols / chemistry
Prodrugs / chemistry,  metabolism*
Propylene Glycol / chemistry
Skin / metabolism
Skin Absorption*
Reg. No./Substance:
0/3-phosphonooxymethylbuparvaquone; 0/Antiprotozoal Agents; 0/Melanins; 0/Myristates; 0/Naphthoquinones; 0/Phosphoric Acid Esters; 0/Polyethylene Glycols; 0/Prodrugs; 110-27-0/isopropyl myristate; 57-55-6/Propylene Glycol; 64-17-5/Ethanol; 88426-33-9/buparvaquone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Modification of the crystal habit of celecoxib for improved processability.
Next Document:  Image analysis by pulse coupled neural networks (PCNN)--a novel approach in granule size characteriz...